InMode (NASDAQ: INMD)
InMode Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
InMode Company Info
InMode's platforms provide effective treatments for aesthetic conditions without requiring patients to go under a scalpel.
News & Analysis
InMode Beats Earnings, Cuts Guidance
InMode reported mixed Q3 2024 earnings, exceeding revenue expectations but adjusting down annual guidance amid macro challenges.
InMode Ltd. Revenue, Profit Plunge
InMode Ltd. reported a significant year-over-year decline in revenue and profit in its Q2 2024 earnings release, adjusting full-year guidance downward.
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
You should do your best to avoid making similar mistakes too.
2 Small-Cap Stocks With Big Potential in 2024
These companies could experience strong growth next year.
Got $5,000? Here's 3 Reasons to Buy InMode Stock Right Now
Significant drivers of growth are developing, and they'll soon yield fruit.
This 1 Number Shows Why InMode Stock Is a Buy
Revenue is picking up in one of its core segments for its long-term performance.
Is It Too Late to Buy InMode Stock?
Shares of the aesthetics industry's favorite medical technology provider are already up 64% over the past 12 months.
Here's Why I'm Buying (More) InMode Stock in August
There's an interesting catalyst in the making that might drive even more sales.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.